anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Methods and systems of determining relevancy of electronic health records to medical analysis objectives. One system includes an electronic processor configured to access electronic health records and extract medical summary data items from the records. The electronic processor is also configured to determine a set of semantic vectors, where each semantic vector represents a medical summary data item. The electronic processor is also configured to determine a set of anatomical semantic vectors. The electronic processor is also configured to determine a similarity score for each medical summary data item. The electronic processor is also configured to receive a medical study and determine a relevancy score for each medical summary data item, the relevancy score representing a relevancy of each medical summary data item to the medical study. The electronic processor is also configured to generate and transmit a notification to a reviewer of the medical study.
BACKGROUND: As end-stage renal disease becomes more prevalent in the United States, the number of Americans with arteriovenous (AV) fistulas continues to increase. One of the most feared complications of AV fistulas is life-threatening hemorrhage, as patients can exsanguinate within minutes.
OBJECTIVES: As frontline healthcare workers, emergency medicine (EM) providers need to be able to provide rapid and effective treatment for this rare presentation. We developed a task trainer model to simulate AV fistula hemorrhage to prepare and train EM residents.
METHODS: This task trainer model was constructed with readily available materials and takes about 30 minutes to make. Twenty-one EM residents participated in the training session. The session consisted of a brief didactic on AV fistula hemorrhage control followed by hands on usage of the task-trainer model. The participants filled out an anonymous survey afterwards rating the model.
RESULTS: Residents completed anonymous postcourse surveys rating the session on a five-point Likert scale. Both the overall teaching session and the task trainer were rated very highly. Compared to precourse ratings, residents reported statistically significant postcourse improvements in their level of confidence in managing AV fistula hemorrhage.
CONCLUSIONS: To our knowledge, this is the first published task trainer model to simulate a bleeding AV fistula for EM residents. The model was well received by our trainees, is relatively inexpensive, and made from easily sourced materials. We believe this model can be used for trainees of all disciplines to prepare them for this potentially catastrophic patient presentation.
The present invention relates to a cordyceps capsule preparation and its preparation method. Said cordyceps capsule is composed of 1-3 portions of wild cordyceps powder and 3-12 portions of artificial cordyceps mycelium powder through a certain compounding process. Its health-care effect is approaching to that of wild pure cordyceps, and its production cost can be greatly reduced. When the above-mentioned powders are prepared, firstly, the temp. can be reduced to 10 deg.C - -50 deg.C, then the temp. can be quickly reduced to -100 deg.C - -130 deg.C and retained for 20-30 min. to make water content less than 1%, the pulverized to obtain the invented powder preparation whose effective component content is higher than that of cordyceps powder prepared by using general method, and its utilization rate of medicinal material also is raised.
The invention discloses a Miao medicine composition for moxibustion and a preparation method and application thereof. The composition comprises moxa, black vine, raw kusnezoff monkshood root, garden balsam stem, sargentgloryvine stem and Chinese alangium root. The preparation method comprises the following steps: pulverizing caulis Marsdeniae Tenacissimae, radix Aconiti Kusnezoffii, herba speranskiae tuberculatae, caulis Sargentodoxae, and Alangium chinense (L.) seem into fine powder, stirring according to formula, mixing thoroughly, and compression molding. The invention adopts two different moxibustion methods of crossbow drug moxibustion and moxa stick moxibustion, and the curative effect is compared, and the result shows that the crossbow drug moxibustion therapy is superior to the moxa stick moxibustion, and the difference has statistical significance, so that the clinical curative effect of the crossbow drug moxa stick prepared by the invention for improving knee osteoarthritis is superior to that of the traditional moxa stick. And the fire is sustained and flame-resistant, the moxa smoke generated is obviously reduced, the burning time of moxa sticks with the same dosage exceeds three to five times of the burning time of other moxa sticks, the moxibustion force is fast to permeate, the skin is not hot and deep, the moxibustion sense is easy to excite, and the sensing phenomenon occurs. The crossbow drug moxibustion therapy is an expansion application of a common moxibustion method after crossbow drug adding, and the drug-containing moxibustion has the advantages of simple operation, better curative effect and the like, is easy to accept by patients, is suitable for wide popularization in families and communities, and reduces the medical burden of society and individuals.
Participants with type 1 and type 2 diabetes will use a meal tagging application (app) and fitness tracker. They will upload these data to a web portal where they will be matched with data from their insulin pen and continuous glucose monitor (CGM). Combined data will be used as a complement to standard of care for diabetes management.
Patients receive anti-CD19-CAR-T cells to treatment of SLE. The purpose of this study is to assess the safety and efficacy of CD19 CAR-T cells in the treatment of SLE.
Background. Occupational Performance Coaching (OPC) is a goal-oriented approach in which client agency takes precedence in goal selection, analysis, choice of action, and evaluation of success. The intended outcomes of OPC are improved occupational performance and participation in clients' life situations. Randomized clinical trials are needed to determine the effectiveness of OPC. Purpose. This study protocol outlines a randomized controlled trial (RCT) of OPC compared to usual care with caregivers of children with neurodisability in improving child, caregiver, and family occupational performance. Method. A single-blind, 2-arm parallel-group, cluster RCT of OPC compared to usual care is planned. Therapists delivering the intervention (N = 14) are randomized to "OPC training" or "usual care" groups. The primary outcome is occupational performance improvement in caregiver (N = 84) identified goals. Implications. Findings will provide translational evidence of the effectiveness of OPC and clarify intervention processes. Areas of future OPC research and development will be indicated.
Transgender women (TW) are one of the most vulnerable populations for acquiring HIV infection, and the scant available data on transgender men (TM) suggests they are also at risk. TW have accounted for only 0.2% of all participants in bio-behavioral HIV prevention trials using pre-exposure prophylaxis (PrEP), and TM have typically not been included. TW and TM adolescents have received even less attention in PrEP trials.

Although tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), the FDA-approved PrEP drug, would not be expected to interact with cross-sex hormone therapy (cs-HT; estradiol and testosterone) based on known mechanisms and data from studies with hormonal contraceptives, there are no data that prove this. Given this lack of data, TW and TM youth on cs-HT have decreased PrEP uptake and adherence due to concerns that PrEP may reduce the effectiveness of cs-HT. To address these critical scientific gaps in PrEP safety for transgender youth and to plan for appropriate implementation, the investigators propose the following study in 3 integrated phases. In Phase 1, investigators will conduct a PK study exploring the interactions of cs-HT for both TW and TM on TDF/FTC. Simultaneously, in Phase 2, investigators will collect ethnographic data via focus groups and in-depth interviews to inform the development of a tailored gender-affirmative intervention to improve uptake and adherence to PrEP in transgender youth. In Phase 3, investigators will conduct a small demonstration trial of PrEP use in TW and TM youth, utilizing the ethnographically developed intervention to improve uptake and adherence, while also monitoring renal and bone safety outcomes.
PURPOSE: To obtain a remedying agent capable of dramatically curing persistent pruritus through extremely effectively acting on various kinds of dermal pruritus, by incorporating a water-swollen body of sodium montmorillonite as the chief agent With a humectant, oil or crude drug. CONSTITUTION: This remedying agent is obtained by incorporating (A) a water- swollen body of sodium montmorillonite as the chief agent with (B) a humectant (pref. sodium lactate or sorbitol), oil (pref. squalene or rice germ oil) or crude drug (pref. an extract of mugwort or field horsetail). It is preferable in terms of dermal infiltrativity that the water contained in the component A be water small in cluster. It is recommended that this remedying agent be coated in the creamy form or sprayed as a spray.
Patients continue antiretroviral medications throughout the course of this study. Three groups of patients receive dose-escalation (2×10\^9VP, 2×10\^10VP or 2×10\^11VP) injections of Adenovirus vector vaccine (Ad5-gag). Two weeks post immunization of lower dose, if the vaccine is safe and well tolerant, the next dose of immunization will begin. patients are monitored for safety 72 hours after each immunization. In addition, each patient records adverse events in a diary. Patients have regular physical exams, pregnancy tests, and blood drawn for virologic and immunologic assessments. The induction of HIV-specific responses will be measured.
Subjects in this arm received a metallic silver dressing (Acticoat Post-Op®, Smith \& Nephew), a one-piece, peel-and-stick and non-transparent dressing. This dressing is an absorbent postoperative dressing consisting of a nanocrystalline silver-coated polyurethane layer, a white polyurethane foam and an adhesive coated waterproof polyurethane film layer. Acticoat Post-Op may be left in place over a wound for up to 7 days. The manufacturers note that the product should not be used in patients with known silver allergies and that it may cause transient discoloration of the skin.
In permeability lung edema, cardiogenic lung edema or neonatal respiratory distress, there is heterogeneous liquid distribution throughout the lungs. The excess alveolar liquid reduces gas exchange. Mechanical ventilation is used to improve gas exchange. In the presence of heterogeneous liquid distribution, there are surface tension-dependent stress concentrations in septa separating aerated from flooded alveoli. Mechanical ventilation, by inflating the lung above normal volumes, thus increasing surface tension above normal, exacerbates the stress concentrations and consequently injures, or exacerbates pre-existing injury of, the alveolar-capillary barrier. Any means of lowering surface tension should lessen ventilation injury of the lung. In the present invention, dilute exogenous surfactant solution or surfactant protein C solution interacts with albumin to lower surface tension, likely through effective promotion of surfactant lipid adsorption. Dilute surfactant or SP-C solution could be administered via either the trachea or the vasculature. Either solution could be delivered in the absence or presence of albumin or alternative facilitating solute, to lower surface tension and lessen ventilation injury of the heterogeneously flooded lung.
PURPOSE: A composition containing a Dendropanax morbifera leaf extract is provided to promote bowel movement and to treat intestinal diseases such as constipation. CONSTITUTION: A pharmaceutical composition for preventing and treating functional constipation or organic constipation contains a Dendropanax morbifera leaf extract as an active ingredient. The extract is prepared using water, low carbon number Ca-C4 alcohol, or a mixture solvent thereof. Functional constipation includes atonic constipation or spastic constipation. Organic constipation includes stenosis of intestine, sigmoid colon, or megasigmoid. A health functional food for preventing and treating functional constipation or organic constipation contains the extract as an active ingredient. A food additive for preventing and treating functional constipation or organic constipation contains the extract as an active ingredient. [Reference numerals] (AA) Control group; (BB) Low dietary fiber intake group; (CC) Low dietary fiber + dendropanax morbifera leaf extract 100mg/kg; (DD) Low dietary fiber + dendropanax morbifera leaf extract 300mg/kg; (EE) Low dietary fiber + dendropanax morbifera leaf extract 500mg/kg; (FF) Weight of excrement(before drying); (GG) Weight of excrement(after drying); (H1,H2) Negative control group; (I1,I2) Dendropanax morbifera leaf extract 100mg/kg; (J1,J2) Dendropanax morbifera leaf extract 300mg/kg; (K1,K2) Dendropanax morbifera leaf extract 500mg/kg
This is a double blind (a medical research study in which neither the researchers nor the participants know what treatment the participants is receiving), randomized (study drug is assigned by chance), placebo-controlled, parallel group (a medical research study comparing the response in 2 or more groups of participants receiving different interventions \[treatments\]) and up-titration study in participants with chronic low back pain. The study will consist of 6 visits (Day -7 to Day -1 \[Visit 1\], Day 1 \[Visit 2\], Day 3 \[telephone visit\], Day 8 \[Visit 3\], Day 15 \[Visit 4\] and Day 29 \[Visit 5\]) and 2 phases: a screening phase and treatment phase. Screening phase will be of 7 days during which, participants will receive stable dose of non-steroidal anti-inflammatory drugs (NSAIDS) or COX-2 selective inhibitors (NSAID that specifically inhibits an enzyme known as cyclooxygenase-2) for pain therapy. On the basis of average pain intensity over the last 48 hours which will be measured at baseline (at the end of screening period), participants will enter the treatment phase. Treatment phase will be of 28 days which includes 7-days of dose titration period. In treatment phase all participants will be randomly assigned to 1 of 2 possible treatments: tramadol HCl 75 milligram (mg)/acetaminophen 650 mg ER tablet treatment or the equivalent placebo (an inactive substance) treatment until study completion, Day 29. Participants will receive 1 tablet of tramadol HCl/acetaminophen ER or its equivalent placebo, once daily for 3 days. After the first 3 days, the participants will receive a telephone inquiry monitoring the occurrence of adverse events and will be given additional administration instructions for the next 4 days (1 tablet twice daily for 4 days). From Day 7, participants will receive 1 or 2 tablets twice a day depending on the degree of pain relief required. Participants will visit the center on the Day 8 (Visit 3), Day 15 (Visit 4), and Day 29 (Visit 5) after starting study drug. The efficacy will be assessed by measuring extent of reduction in pain intensity on a Visual Analog Scale (VAS). Participants' safety will be monitored throughout the study.
Group I (treatment with our technique) Eighteen patients (18 wrists) were available for long-term follow-up at an average of 47.8 months after surgery. There were 11 men and seven women. Their mean age at the time of surgery was 35.4 years (range, 22 to 56 years). The dominant hand was involved in 12 patients and the nondominant hand, in six.
Participants will receive escalating doses of PYX-201 to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of PYX-201. Intra-participant dose escalation may be considered for participants who have adequately tolerated therapy.
Relating to the technical field of beverage processing, the invention provides a bletilla striata beverage and a preparation method thereof. The bletilla striata beverage is mainly prepared from the following raw materials by weight: 40-70 parts of bletilla striata, 20-30 parts of kudzuvine root, 10-20 parts of Chinese yam, 10-20 parts of germinated brown rice, 5-10 parts of Chinese wolfberry, 5-10 parts of mulberry leaf, 3-5 parts of fructooligosaccharide, and 0.5-2 parts of a flavoring agent. The bletilla striata beverage contains a variety of functional components, is nutritious and safe, and has certain beauty maintaining and health care effects and intestine and stomach coordinating efficacy. In addition, the invention also relates to a preparation method of the bletilla striata beverage. The method includes: conducting superfine grinding on part of the raw materials, then conducting ultrasonic extraction to obtain an extracted solution, carrying out superfine grinding and gelatinization on the germinated brown rice to obtain a rice paste, decocting the Chinese wolfberry and mulberry leaf to obtain an extract, and then carrying out blending, homogenizing, deaeration and sterilization. The preparation method provided by the invention has the characteristics of simplicity and easy operation, and can maximumly retain the nutritional ingredients and functional ingredients of the raw materials.
ADC drugs are a new type of targeted therapy. ADC drugs are composed of monoclonal antibodies, linkers and drug carriers, which bind to the target antigen on the surface of tumor cells through antibodies, endocytosis/internalization to form early endosomes in cells, and then mature into late endosomes and fuse with lysosomes. ADC drugs break apart in the lysosome and release the drug carrier, eventually leading to apoptosis or death while minimizing damage to normal cells. However, not all subjects with HER2-positive breast cancer respond well to ADC drugs, and resistance may develop during treatment. Therefore, effective biomarkers are needed to monitor treatment effects and guide individualized treatment. Serum HER2 refers to the HER2 protein fragment present in the subject's serum. Serum HER2 levels may be more readily available than HER2 expression in tumor tissue and can be sampled multiple times during treatment, allowing real-time monitoring of disease progression and drug efficacy. If monitoring of serum HER2 levels accurately reflects tumor sensitivity to ADC drugs, it could be a valuable therapeutic monitoring tool.

In view of the excellent efficacy of ADC drugs in HER2-positive and low-expression breast cancer patients, this study intends to judge the therapeutic efficacy of breast cancer patients treated by anti-HER2-ADC drugs (such as T-DXd) through continuous detection of their serum HER2, providing a theoretical basis for the selection of clinical drug therapy.
The investigators are proposing a double blind, placebo-controlled trial to establish safety and efficacy of ritlecitinib to prevent gluten-induced celiac enteropathy and symptoms in celiac disease (CeD) patients in remission. The results of this study will impact the therapeutic options in the future for individuals with CeD.

Participants will take placebo capsule or ritlecitinib 200 mg capsule once per day. Both will be taken orally. All participants will take 10g gluten once per day, for a total of 21 days. Gluten will be taken orally by mixing the gluten powder into either hot chocolate or apple sauce. If participant unable to tolerate 10g of gluten daily, they will have the option to decrease to 5g daily after Day 3 of study.
The invention discloses a quantitative determination method of effective ingredients in Salvia miltiorrhiza Bunge injecta. Effective ingredients for quantification comprise sodium danshensu, protocatechualdehyde, salvianolic acid B and salvianolic acid A. The determination step comprises: preparing comparison product solution, preparing test article solution and measuring liquid phase. Color spectrum condition comprises C18 chromatographic column, linear gradient elution program and DAD scanning. The determination method can be used for quality control of Salvia miltiorrhiza Bunge injecta and effectively ensures the quality of Salvia miltiorrhiza Bunge injecta. Large scale market application shows that the Salvia miltiorrhiza Bunge injecta has small adverse reaction, high safety, exact curative effect and controllable quality.
The pharmacokinetic properties of FORTICAL® calcitonin-salmon (rDNA origin) Nasal Spray after multiple dose administration were shown to be similar to that of a commercially available calcitonin-salmon product in healthy volunteers. The bioavailability of calcitonin-salmon nasal spray relative to intramuscular administration is between 3 and 5%. Calcitonin-salmon nasal spray is absorbed by the nasal mucosa with a mean Tmax of about 13 minutes. The terminal half-life of calcitonin-salmon has been calculated to be around 18 minutes and no evidence of accumulation was observed with multiple dosing. Plasma exposure was higher following administration of 400 IU nasal spray compared to that after 200 IU dose. As is the case with other polypeptide hormones, there is very little value in monitoring plasma levels of salmon calcitonin since these are not directly predictive of the therapeutic response. Hence, Fortical® activity should be evaluated by using clinical parameters of efficacy.
Mild traumatic brain injury (mTBI) is known to result in chronic somatic, cognitive, and emotional symptoms. Depression is commonly reported among individuals suffering from persistent concussion symptoms; however, the underlying mechanisms are not understood. The glutamatergic system has recently been linked with mTBI and depression due to reports of similar changes in expression of glutamatergic proteins. Using a closed-head controlled cortical impact (cCCI) model in adult male rats (n = 8/group), this study investigated the emergence of self-care deficits and changes in social interaction behaviors at four, eight and twelve weeks post-injury. Western blotting was used to assess associated changes in expression of glutamate transporters and N-methyl-D-aspartate (NMDA) receptor subunits at twelve weeks. Splash test results revealed deficits in self-care behaviors beginning at eight weeks, which continued through twelve weeks in the injury group. Injured animals also exhibited decreased preference for social novelty at four weeks and loss of desire for social interaction as a whole by twelve weeks. GluN1 was increased in injured animals compared to shams in the frontal cortex and amygdala, while decreased GLT-1 was observed in the hippocampus. Linear regression was performed to evaluate relationships between behavioral and molecular variables; the results suggested that injury affects these relationships in a region-dependent manner. Together, these results suggest that the development of chronic depression-like behavior was associated with changes in glutamatergic protein expression. Deeper investigations into how injury influences glutamatergic synaptic protein expression are needed, as this has the potential to affect circuit-level neurotransmission that drives depression-like behavior following mTBI.